Drug Trial Radar · NCT03859921
Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET
Last checked: Nov 20, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
716
Planned (sponsor's estimate)
Start
Jul 1, 2021
Primary completion
Dec 30, 2025
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 42 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomised double-blinded controlled trial aims to compare the live birth rate in natural FET cycles with and without oral dydrogesterone as luteal phase support. The hypothesis is that the use of oral dydrogesterone will increase the live birth rate of natural cycle FET.
Conditions
- Subfertility
Interventions
DydrogesteroneDrug
Progesterone
PlaceboDrug
Placebo with appearance similar to Dydrogesterone
Primary outcomes
What the sponsor says the trial is designed to measure.
- live birth rateTime frame: 10 months after recruitment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Obstetrics and Gynaecology
Hong Kong, Hong Kong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.